American Healthcare REIT, Inc. (the "Company," "we," "our," "management," or "us") announced today its fourth quarter and full year 2024 results and is issuing full year 2025 ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice.

Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation. Leukemia. 2025;1-11.

Correspondingly, AASs were associated with an increased risk of acute myocardial infarction (adjusted hazard ratio [aHR] 3.00 [95% CI, 1.67–5.39]), percutaneous coronary intervention or coronary ...

T-Mobile is one of the fastest-growing carriers in the United States thanks to aggressive pricing, marketing, and a penchant for doing the unexpected. The Uncarrier has significantly shaken up the ...

In August 2022, T-Mobile and SpaceX announced a bold plan to expand cellular connectivity across the US with the help of low-orbit satellites. Fast-forward to 2025, and the T-Mobile Starlink ...

See a doctor who has experience with it. You’ll find dermatologists who have experience with cutaneous T-cell lymphoma at Find a Dermatologist. Click on "Filters". Select "Any condition" and choose ...

In some experiments, mice were administered recombinant IFN or adoptively transferred with plasmacytoid dendritic cells (pDC). Results Allergic Tlr7 −/− mice displayed ... and patients with a RAST ...

In general, chemotherapy medications work by attacking cells or by preventing them from ... When this occurs, your blood isn’t able to clot properly, which can lead to excessive bleeding.

Newly discovered brain cells count each bite before sending the ... "Interestingly, these neurons don't just signal an immediate stop; they help the mice to slow down their eating gradually ...

It can feel a little overwhelming, even though they're often slow or difficult to unlock and discover. That's where a Dead Cells weapons tier list comes in. While we haven't gone into detail about ...